scholarly article | Q13442814 |
P2093 | author name string | Dominique Douguet | |
Philippe Diaz | |||
Robert S Foti | |||
P2860 | cites work | Mechanisms of retinoid resistance in leukemic cells: possible role of cytochrome P450 and P-glycoprotein | Q70884452 |
Inhibition of all-trans-retinoic acid metabolism by fluconazole in vitro and in patients with acute promyelocytic leukemia | Q71781078 | ||
Human cytochrome P-450 metabolism of retinals to retinoic acids | Q73462664 | ||
Biosynthesis of all-trans-retinoic acid from all-trans-retinol: catalysis of all-trans-retinol oxidation by human P-450 cytochromes | Q73462675 | ||
Extensive binding of the bioflavonoid quercetin to human plasma proteins | Q74410720 | ||
Participation of CYP2C8 in retinoic acid 4-hydroxylation in human hepatic microsomes | Q78251664 | ||
Use of an induced fit receptor structure in virtual screening | Q82621813 | ||
Homology models of human all-trans retinoic acid metabolizing enzymes CYP26B1 and CYP26B1 spliced variant | Q84981035 | ||
Homology Models and Molecular Modeling of Human Retinoic Acid Metabolizing Enzymes Cytochrome P450 26A1 (CYP26A1) and P450 26B1 (CYP26B1) | Q86833538 | ||
Identification of the human cytochrome P450, P450RAI-2, which is predominantly expressed in the adult cerebellum and is responsible for all-trans-retinoic acid metabolism | Q22254142 | ||
A Novel Human Cytochrome P450, CYP26C1, Involved in Metabolism of 9-cis and All-trans Isomers of Retinoic Acid | Q24297212 | ||
Retinoic acid synthesis and signaling during early organogenesis | Q24642848 | ||
Mechanisms of retinoic acid signalling and its roles in organ and limb development | Q27014957 | ||
Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site | Q27642793 | ||
Determinants of Cytochrome P450 2C8 Substrate Binding: STRUCTURES OF COMPLEXES WITH MONTELUKAST, TROGLITAZONE, FELODIPINE, AND 9-CIS-RETINOIC ACID | Q27650327 | ||
Identification of Tazarotenic Acid as the First Xenobiotic Substrate of Human Retinoic Acid Hydroxylase CYP26A1 and CYP26B1 | Q28115020 | ||
Human retinoic acid (RA) 4-hydroxylase (CYP26) is highly specific for all-trans-RA and can be induced through RA receptors in human breast and colon carcinoma cells | Q28115699 | ||
Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites | Q28138601 | ||
Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation | Q28139603 | ||
CYP26, a novel mammalian cytochrome P450, is induced by retinoic acid and defines a new family | Q28244060 | ||
Homology model of human retinoic acid metabolising enzyme cytochrome P450 26A1 (CYP26A1): active site architecture and ligand binding | Q28270093 | ||
Metabolism of retinol and retinoic acid by human liver cytochrome P450IIC8 | Q28284393 | ||
Examination of 209 drugs for inhibition of cytochrome P450 2C8 | Q28298519 | ||
9-Cis retinoic acid stereoisomer binds and activates the nuclear receptor RXRα | Q28343032 | ||
Characterization of three RXR genes that mediate the action of 9-cis retinoic acid | Q28343068 | ||
Novel procedure for modeling ligand/receptor induced fit effects. | Q30352584 | ||
Retinoic acid metabolism inhibition by 3-azolylmethyl-1H-indoles and 2, 3 or 5-(alpha-azolylbenzyl)-1H-indoles | Q30732753 | ||
Cytochrome p450 retinoic acid 4-hydroxylase inhibitors: potential agents for cancer therapy | Q30737013 | ||
A comparison of the roles of peroxisome proliferator-activated receptor and retinoic acid receptor on CYP26 regulation | Q33613386 | ||
Expression and functional characterization of cytochrome P450 26A1, a retinoic acid hydroxylase | Q33690947 | ||
Regulation of retinoic acid signaling in the embryonic nervous system: a master differentiation factor | Q33922396 | ||
Retinoids in embryonal development | Q33967658 | ||
The relative importance of CYP26A1 in hepatic clearance of all-trans retinoic acid | Q34005757 | ||
Clotrimazole: a review of its antifungal activity and therapeutic efficacy | Q34022854 | ||
Therapeutic potential of the inhibition of the retinoic acid hydroxylases CYP26A1 and CYP26B1 by xenobiotics | Q34345596 | ||
Quantifying and predicting the promiscuity and isoform specificity of small-molecule cytochrome P450 inhibitors | Q34359495 | ||
Retinoids for the treatment of psoriasis: outlook for the future. | Q34379312 | ||
Clinical pharmacokinetics of candesartan | Q34515194 | ||
Gemfibrozil greatly increases plasma concentrations of cerivastatin | Q34530003 | ||
The role of vitamin A in mammalian reproduction and embryonic development | Q34676020 | ||
Retinoid signalling in the development of the central nervous system | Q34988289 | ||
Retinoic acid metabolism and mechanism of action: a review | Q35061108 | ||
Substrate specificity and ligand interactions of CYP26A1, the human liver retinoic acid hydroxylase | Q35122815 | ||
The Conduct of In Vitro and In Vivo Drug-Drug Interaction Studies: A PhRMA Perspective | Q35129048 | ||
Comparison of the function and expression of CYP26A1 and CYP26B1, the two retinoic acid hydroxylases | Q35589480 | ||
First chemical feature-based pharmacophore modeling of potent retinoidal retinoic acid metabolism blocking agents (RAMBAs): identification of novel RAMBA scaffolds. | Q35675265 | ||
CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast | Q35718619 | ||
Experimental studies with liarozole (R 75,251): an antitumoral agent which inhibits retinoic acid breakdown | Q35834599 | ||
Cytochrome p450: a target for drug development for skin diseases | Q35860199 | ||
Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance | Q36131028 | ||
Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype. | Q36304459 | ||
Retinoic acid induces Sertoli cell paracrine signals for spermatogonia differentiation but cell autonomously drives spermatocyte meiosis | Q36339894 | ||
Function of retinoid nuclear receptors: lessons from genetic and pharmacological dissections of the retinoic acid signaling pathway during mouse embryogenesis | Q36364699 | ||
Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases. | Q36418564 | ||
Stereoselective formation and metabolism of 4-hydroxy-retinoic Acid enantiomers by cytochrome p450 enzymes | Q36452010 | ||
RAR and RXR modulation in cancer and metabolic disease | Q36956230 | ||
Retinoic acid metabolism blocking agents (RAMBAs): a new paradigm in the treatment of hyperkeratotic disorders | Q36973819 | ||
Cytochrome P450s in the regulation of cellular retinoic acid metabolism | Q37212128 | ||
The role of CYP26 enzymes in retinoic acid clearance | Q37313897 | ||
Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms | Q37705508 | ||
The rhythm of retinoids in the brain | Q38165261 | ||
Modulation of T cell and innate immune responses by retinoic Acid | Q38198610 | ||
Differential contribution of active site residues in substrate recognition sites 1 and 5 to cytochrome P450 2C8 substrate selectivity and regioselectivity | Q38340129 | ||
Quercetin pharmacokinetics in humans | Q38502477 | ||
Design, synthesis, and biological evaluation of amide imidazole derivatives as novel metabolic enzyme CYP26A1 inhibitors | Q38964443 | ||
Novel retinoic acid 4-hydroxylase (CYP26) inhibitors based on a 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-(4-(phenylamino)phenyl)propyl scaffold | Q39326501 | ||
Small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26): synthesis and biological evaluation of imidazole methyl 3-(4-(aryl-2-ylamino)phenyl)propanoates | Q39572100 | ||
Novel azolyl-(phenylmethyl)]aryl/heteroarylamines: potent CYP26 inhibitors and enhancers of all-trans retinoic acid activity in neuroblastoma cells | Q39947857 | ||
Expression of RALDHs (ALDH1As) and CYP26s in human tissues and during the neural differentiation of P19 embryonal carcinoma stem cell | Q39978813 | ||
Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells | Q40282939 | ||
The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer | Q40839068 | ||
Catalysis of the 4-hydroxylation of retinoic acids by cyp3a7 in human fetal hepatic tissues. | Q40860308 | ||
Bioequivalence of two oral contraceptive drugs containing norethindrone and ethinyl estradiol | Q41286094 | ||
Molecular recognition of CYP26A1 binding pockets and structure-activity relationship studies for design of potent and selective retinoic acid metabolism blocking agents | Q41648591 | ||
Catalytic versus inhibitory promiscuity in cytochrome P450s: implications for evolution of new function | Q41995930 | ||
Functional properties and substrate characterization of human CYP26A1, CYP26B1, and CYP26C1 expressed by recombinant baculovirus in insect cells | Q42726934 | ||
Benzbromarone Pharmacokinetics and Pharmacodynamics in Différent Cytochrome P450 2C9 Genotypes | Q42852451 | ||
Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast | Q42997336 | ||
Relevance of nonsynonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation. | Q43084915 | ||
Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate | Q43503022 | ||
Antifungal triazoles induce malformations in vitro | Q43698767 | ||
Role of retinoids in differentiation and carcinogenesis. | Q43700097 | ||
Human cytochrome P450s involved in the metabolism of 9-cis- and 13-cis-retinoic acids | Q43930670 | ||
Cloning of rat cytochrome P450RAI (CYP26) cDNA and regulation of its gene expression by all-trans-retinoic acid in vivo | Q44020686 | ||
Interaction of all-trans-retinoic acid with fluconazole in acute promyelocytic leukemia | Q44449057 | ||
Gemfibrozil considerably increases the plasma concentrations of rosiglitazone | Q44536345 | ||
Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays | Q44870129 | ||
Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants | Q45174835 | ||
Fluconazole alters CYP26 gene expression in mouse embryos. | Q46017769 | ||
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone | Q46496013 | ||
Murine teratology of fluconazole: evaluation of developmental phase specificity and dose dependence. | Q46497275 | ||
Retinoic acid in development: towards an integrated view | Q46549138 | ||
The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo | Q46664324 | ||
Effect of gemfibrozil on the pharmacokinetics of pioglitazone | Q46800471 | ||
The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective | Q47819795 | ||
Retinoid metabolism in the skin. | Q47906563 | ||
Benzbromarone disposition and uricosuric action; evidence for hydroxilation instead of debromination to benzarone. | Q51626478 | ||
Retinoic acid receptors: from molecular mechanisms to cancer therapy. | Q52656210 | ||
Evaluation of cytochrome P450-mediated drug-drug interactions based on the strategies recommended by regulatory authorities. | Q53203053 | ||
Dose-Dependent Interaction between Gemfibrozil and Repaglinide in Humans: Strong Inhibition of CYP2C8 with Subtherapeutic Gemfibrozil Doses | Q57825122 | ||
Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide | Q57825160 | ||
Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes | Q59153155 | ||
The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast | Q60449842 | ||
Inhibition of retinoic acid metabolism by imidazole antimycotics in F9 embryonal carcinoma cells | Q69051552 | ||
Retinoic acid improves epidermal morphogenesis | Q69075180 | ||
Second branchial arch anomalies induced by fluconazole, a bis-triazole antifungal agent, in cultured mouse embryos | Q70675473 | ||
P433 | issue | sup2 | |
P921 | main subject | tretinoin | Q29417 |
ligand binding | Q61659151 | ||
P304 | page(s) | 148-161 | |
P577 | publication date | 2016-07-17 | |
P1433 | published in | Journal of Enzyme Inhibition and Medicinal Chemistry | Q15708877 |
P1476 | title | Comparison of the ligand binding site of CYP2C8 with CYP26A1 and CYP26B1: a structural basis for the identification of new inhibitors of the retinoic acid hydroxylases. | |
P478 | volume | 31 |